Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1012780

USP

Alendronate sodium

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Alendronate sodium trihydrate, 4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid, monosodium, MK-217

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C4H12NaNO7P2 · 3 H2O
Número de CAS:
121268-17-5
Peso molecular:
325.12
MDL number:
MFCD01748233
UNSPSC Code:
41116107
PubChem Substance ID:
329748953
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

alendronate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

InChI key

DCSBSVSZJRSITC-UHFFFAOYSA-M

Gene Information

human ... FDPS(2224)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Alendronate sodium is a primary amino bisphosphonate.

Application

Alendronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Alendronate sodium trihydrate is a bone resorption inhibitor; farnesyl diphosphate synthase inhibitor (IC50 = 460 nM); CD45 protein tyrosine phosphatase inhibitor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

S O Işeri et al.
The Journal of endocrinology, 187(3), 399-406 (2006-01-21)
Alendronate sodium, a primary amino bisphosphonate, is widely used in the treatment of various diseases that are associated with bone resorption, such as postmenopausal osteoporosis and Paget's disease of bone. Although the adverse effects of biphosphonates on the gastrointestinal system
V Lezcano et al.
Experimental cell research, 324(1), 30-39 (2014-04-05)
Bisphosphonates (BPs), potent inhibitors of bone resorption which inhibit osteoclasts, have also been shown to act on osteocytes and osteoblasts preventing apoptosis via connexin (Cx) 43 hemichannels and activating the extracellular signal regulated kinases ERKs. We previously demonstrated the presence
Kazuhiro Imai
Clinical interventions in aging, 8, 681-688 (2013-06-15)
Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age, especially in postmenopausal women. Japan is one of the most rapidly aging societies worldwide.
Nisarg J Shah et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(35), 12847-12852 (2014-08-20)
Traumatic wounds and congenital defects that require large-scale bone tissue repair have few successful clinical therapies, particularly for craniomaxillofacial defects. Although bioactive materials have demonstrated alternative approaches to tissue repair, an optimized materials system for reproducible, safe, and targeted repair
Caroline Houston et al.
Muscle & nerve, 49(4), 506-511 (2013-07-10)
Patients with DMD have low bone mineral density (BMD) and are at high risk for fractures. We examined changes in BMD and the effects of alendronate in DMD patients treated at our institution in the last decade. Retrospective cohort study
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico